MiMedx logo

MiMedxNASDAQ: MDXG

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

12 February 2008

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.35 B
-2%vs. 3y high
77%vs. sector
-35%vs. 3y high
23%vs. sector
-99%vs. 3y high
89%vs. sector
-8%vs. 3y high
56%vs. sector

Price

after hours | Sat, 16 Nov 2024 00:56:42 GMT
$9.21-$0.23(-2.44%)

Dividend

No data over the past 3 years
$84.06 M$89.42 M
$84.06 M$8.10 M

Analysts recommendations

Institutional Ownership

MDXG Latest News

MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs
globenewswire.com14 November 2024 Sentiment: POSITIVE

Over 200 Unproven Skin Substitutes Will No Longer Be Covered Under Revised LCDs Company to Benefit from MACs' Commitment to Clinically Effective, Proven Products MARIETTA, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today provided the following update on the Local Coverage Determinations (“LCDs”) regarding “Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers.

Can MiMedx (MDXG) Climb 77.92% to Reach the Level Wall Street Analysts Expect?
zacks.com04 November 2024 Sentiment: POSITIVE

The consensus price target hints at a 77.9% upside potential for MiMedx (MDXG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

MiMedx (MDXG) Q3 Earnings and Revenues Surpass Estimates
zacks.com30 October 2024 Sentiment: POSITIVE

MiMedx (MDXG) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.05 per share a year ago.

MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30
globenewswire.com14 October 2024 Sentiment: POSITIVE

MARIETTA, Ga., Oct. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2024 after the market close on Wednesday, October 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue
globenewswire.com08 October 2024 Sentiment: POSITIVE

MARIETTA, Ga., Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today highlighted the publication of a feature article on placental allografts for patients with hard-to-heal, acute and chronic wounds, which was published in today's New York Times: “Her Face Was Unrecognizable After an Explosion.

MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall
globenewswire.com01 October 2024 Sentiment: POSITIVE

Company to Sponsor Lunch Symposium and Hands-On Skills Lab Featuring Seven Accepted Posters, Further Expanding Its Best-In-Class Portfolio of Clinical and Scientific Research   MARIETTA, Ga., Oct. 01, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place October 2-5 in Las Vegas, NV.

THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'
prnewswire.com04 September 2024 Sentiment: NEGATIVE

Ex-MiMedx Employee Jake Heikkinen Files Counterclaims Alleging Schemes 'To Bilk Medicare' and 'Incentivize and Pressure Healthcare Providers' per Mintz Attorneys MARIETTA, Ga. , Sept. 4, 2024 /PRNewswire/ -- The third of 10 defendants who were sued earlier this year by MiMedx Group, Inc. (NASDAQ: MDXG) today filed counterclaims against the company.

DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT
prnewswire.com26 August 2024 Sentiment: NEGATIVE

Ex-MiMedx Employee Caralyn Gargan Files Counterclaims for "Predatory Sales Practices" and "Incentivized Fraud" per Mintz Attorneys MARIETTA, Ga. , Aug. 26, 2024 /PRNewswire/ -- One of 10 defendants who were sued earlier this year by MiMedx Group, Inc. (NASDAQ: MDXG) today filed counterclaims against the placental biologics company.

MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix
globenewswire.com31 July 2024 Sentiment: POSITIVE

Limited market release marks first xenograft addition to Company's portfolio of leading Wound and Surgical products Limited market release marks first xenograft addition to Company's portfolio of leading Wound and Surgical products

MIMEDX Announces Second Quarter 2024 Operating and Financial Results
globenewswire.com31 July 2024 Sentiment: POSITIVE

Net Sales of $87 Million Grew 7% Year-Over-Year for the Second Quarter Second Quarter GAAP Net Income and Earnings Per Share were $18 Million and $0.12 , Respectively Second Quarter Adjusted EBITDA was $20 Million, or 23% of Net Sales Management to Host Conference Call Today, July 31, 2024 , at 4:30 PM ET MARIETTA, Ga., July 31, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the second quarter 2024.

What type of business is MiMedx?

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

What sector is MiMedx in?

MiMedx is in the Healthcare sector

What industry is MiMedx in?

MiMedx is in the Biotechnology industry

What country is MiMedx from?

MiMedx is headquartered in United States

When did MiMedx go public?

MiMedx initial public offering (IPO) was on 12 February 2008

What is MiMedx website?

https://www.mimedx.com

Is MiMedx in the S&P 500?

No, MiMedx is not included in the S&P 500 index

Is MiMedx in the NASDAQ 100?

No, MiMedx is not included in the NASDAQ 100 index

Is MiMedx in the Dow Jones?

No, MiMedx is not included in the Dow Jones index

When was MiMedx the previous earnings report?

No data

When does MiMedx earnings report?

The next expected earnings date for MiMedx is 28 February 2025